Get started
Author

Luigi Fattore

MicroRNAs in melanoma development and resistance to target therapy
2017 · Luigi Fattore, Susan Costantini, et al. · Oncotarget · 116
PDF
miR-579-3p controls melanoma progression and resistance to target therapy
2016 · Luigi Fattore, Rita Mancini, et al. · Proceedings of the National Academy of Sciences · 112
PDF
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
2018 · Maria Elena Pisanu, Marcello Maugeri-Saccà, et al. · Journal of Experimental & Clinical Cancer Research · 89
PDF
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
2018 · Luigi Fattore, Ciro Francesco Ruggiero, et al. · Cell Death and Differentiation · 71
PDF
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
2013 · Luigi Fattore, Emanuele Marra, et al. · Journal of Translational Medicine · 68
PDF
Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
2019 · Luigi Fattore, Ciro Francesco Ruggiero, et al. · Cell Death and Disease · 50
PDF
Selective targeting of point-mutated KRAS through artificial microRNAs
2017 · Mario Acunzo, Giulia Romano, et al. · Proceedings of the National Academy of Sciences · 49
Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
2022 · Luigi Fattore, Giordana Cafaro, et al. · Oncogene · 48
PDF
microRNA-378a-5p iS a novel positive regulator of melanoma progression
2020 · Maria Grazia Tupone, Simona D’Aguanno, et al. · Oncogenesis · 47
PDF
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
2017 · Vera Hirsh, Sandro Pignata, et al. · Journal of Translational Medicine · 43
PDF
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
2013 · Alessia Noto, Claudia De Vitis, et al. · Oncotarget · 43
PDF
Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR)
2014 · Paola Costanzo, Antonello Santini, et al. · Food and Chemical Toxicology · 41
TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung
2013 · Alberto Ricci*, Claudia De Vitis*, et al. · Cell Cycle · 37
PDF
MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma
2017 · Luigi Fattore, Andrea Sacconi, et al. · Cytokine & Growth Factor Reviews · 36
Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells
2012 · Francesca Belleudi, Emanuele Marra, et al. · Cell Cycle · 35
PDF
The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
2021 · Luigi Fattore, Ciro Francesco Ruggiero, et al. · Frontiers in Oncology · 33
PDF
CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions
2019 · Sara Bruschini, Simona di Martino, et al. · Journal of Cellular Physiology · 33
PDF
ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
2019 · Ciro Francesco Ruggiero, Debora Malpicci, et al. · Cancers · 32
PDF
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma
2022 · Ciro Francesco Ruggiero, Luigi Fattore, et al. · Theranostics · 31
PDF
In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma
2020 · Luigi Fattore, Virginia Campani, et al. · International Journal of Molecular Sciences · 29
PDF
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
2015 · Luigi Fattore, Debora Malpicci, et al. · Oncotarget · 29
PDF
Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
2020 · Luigi Fattore, Rita Mancini, et al. · Cancers · 28
PDF
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
2018 · David Carbone, Michael Sharpnack, et al. · Journal of Translational Medicine · 28
PDF
Role of WT1–ZNF224 interaction in the expression of apoptosis-regulating genes
2013 · Giorgia Montano, Elena Cesaro, et al. · Human Molecular Genetics · 24
Melanoma and immunotherapy bridge 2015: Naples, Italy. 1–5 December 2015
2016 · Vashisht G. Y. Nanda, Weiyi Peng, et al. · Journal of Translational Medicine · 23
PDF
Works count: 68
Citation count: 1,405
H-index: 24
I10-index: 35
Year
Topic
Type